



## Biomedical and Health Informatics Lecture Series

## Tuesday, March 30, 2010 12:00 - 12:50 p.m., Room RR-134

## Beth Devine, PharmD, MBA, PhD, BCPS, FASHP

Research Associate Professor, Pharmaceutical Outcomes Research & Policy Program Department of Pharmacy, University of Washington, Seattle

## "An Indirect Treatment Comparison of Biologic Therapies in Rheumatoid Arthritis"

Dr. Devine will be sharing her recent work exploring emerging statistical methods to conduct indirect and mixed treatment comparisons in the context of comparative effectiveness research. Using a Bayesian framework, indirect and mixed treatment comparisons enable investigators and stakeholders to compare two or more interventions when no head-to-head (direct) randomized controlled trials have been conducted. Indirect/mixed treatment comparisons are an extension of traditional meta-analytic methods to compare more than two interventions, and to rank order these. This method holds promise in the context of future healthcare decision-making under uncertainty and with limited information. Dr. Devine currently serves on a task force of the International Society for Pharmacoeconomics and Outcomes Research that is bringing standardization to this field by publishing two white papers this year.

Dr. Devine joined BHI as an adjunct faculty member in 2009. Her primary faculty appointment is in the UW Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy. She is a member of the UW Centers for Comparative and Health Systems Effectiveness (UW CHASE Alliance; <a href="http://depts.washington.edu/chaseall/">http://depts.washington.edu/chaseall/</a>). In addition to indirect treatment comparisons, Dr. Devine's research interests are centered at the intersection of health information technology and medication safety, for which she is supported by her Mentored Clinical Scientist Training Grant (K-08) from the Agency for Healthcare Research and Quality. Dr. Devine holds a PharmD from the University of the Pacific, an MBA from the University of San Francisco and a PhD in Health Services from the UW School of Public Health. She has completed both a clinical pharmacy residency and a post-doctoral fellowship in Pharmacoeconomics and Outcomes Research, spending one year at Roche Pharma Business, Health Economics and Strategic Pricing Group in Palo Alto, CA. Before turning to her research career at UW she practiced clinical pharmacy at UCSF with advanced practice (prescribing) privileges, and served in Pharmacy Administration.